Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Cold Harbor JV developing copper chelator for Wilson's disease

Jennie Walters
July 13, 2018 6:55 PM UTC

DepYmed Inc., a joint venture between Cold Spring Harbor Laboratory and Ohr Pharmaceutical Inc. (NASDAQ:OHRP), is developing its protein tyrosine phosphatase 1B (PTP-1B; PTPN1) inhibitor DPM-1001 as a copper chelator for Wilson's disease. In a Genes & Development study, Cold Spring Harbor researchers showed the compound reduced disease-associated copper levels and cell damage.

Wilson's disease is characterized by liver and brain deficits from accumulation of copper caused by mutations in ATPase Cu++ transporting beta polypeptide (ATP7B)...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Cold Spring Harbor Laboratory

Ohr Pharmaceutical Inc.